Synthis Therapeutics
PrivateLast Round
Accelerator
Feb 27, 2023
Total Funding Raised
$2.02M
Company Overview
Synthis Therapeutics operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was an Accelerator round in February 2023.
Synthis Therapeutics is a biotechnology company developing antibody-drug conjugates (ADCs) that selectively inhibit TGF-ß for the treatment of cancer and fibrotic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Synthis Therapeutics Comparables
Compare Synthis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GSK plc | 77% | |
| Aarvik Therapeutics | 76% | |
| Alentis Therapeutics | 73% |
For institutional investors. Book with your work email.
Synthis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Feb 27, 2023 | ||||
| Grant | Sep 15, 2022 | ||||
| Grant | Mar 26, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Synthis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| NIH RADx | Grant |
| Johnson & Johnson Innovation - JLABS | Accelerator |
| California Life Sciences | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 15, 2022
$300K grant received from NIH RADx.
- Mar 26, 2021
$300K grant from the National Cancer Institute.
For institutional investors. Book with your work email.
Synthis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Synthis Therapeutics's valuation, stock price, and market status.
Is Synthis Therapeutics a public or private company?
Synthis Therapeutics is a private company.
What is the current stock price of Synthis Therapeutics?
Synthis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Synthis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Synthis Therapeutics worth (valuation)?
Valuation information for Synthis Therapeutics is not publicly available.
Can I buy Synthis Therapeutics stock?
Synthis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Synthis Therapeutics's last funding round?
Synthis Therapeutics's most recent funding round was Accelerator on February 27, 2023.
Who are the main investors in Synthis Therapeutics?
Key investors in Synthis Therapeutics include National Cancer Institute, NIH RADx, Johnson & Johnson Innovation - JLABS, California Life Sciences.
Will Synthis Therapeutics IPO soon?
No public IPO plans have been announced for Synthis Therapeutics.
How can I track Synthis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Synthis Therapeutics's shares on secondary markets.